Floatz logo

Glembatumumab Vedotin

HER2/Neu Negative

National Cancer Institute (NCI)antibody_drug_conjugatePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

192 Active assets in the HER2/Neu Negative cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Glembatumumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Stage IV Uveal Melanoma AJCC v7Dormant
B
Indicative ·
62 / 100
View asset →
uveal melanomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →